Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Catalyst Pharmaceuticals (CPRX) stocks in Canada

Learn how to easily invest in Catalyst Pharmaceuticals stocks.

Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals stocks (CPRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.14 – a decrease of 4.88% over the previous week. Catalyst Pharmaceuticals employs 74 staff and has a trailing 12-month revenue of around $133.5 million.

How to buy shares in Catalyst Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CPRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Catalyst Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Catalyst Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $6.24, which is 16.51% up on its pre-crash value of $5.21 and 144.71% up on the lowest point reached during the March crash when the stocks fell as low as $2.55.

If you had bought $1,000 worth of Catalyst Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $743.47 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,482.19.

Catalyst Pharmaceuticals stock price (NASDAQ:CPRX)

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

Information last updated 2022-01-09.
Latest market close$6.24
52-week range$3.27 - $7.58
50-day moving average $6.83
200-day moving average $5.73
Wall St. target price$10.00
PE ratio 16.8638
Dividend yield N/A (0%)
Earnings per share (TTM) $0.39

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the close of $6.24 from 2022-01-14

1 week (2022-01-07) -4.88%
1 month (2021-12-15) -9.83%
3 months (2021-10-15) 3.48%
6 months (2021-07-15) 13.04%
1 year (2021-01-15) 78.80%
2 years (2020-01-15) 42.14%
3 years (2019-01-15) 142.80%
5 years (2017-01-13) 403.23%

Is Catalyst Pharmaceuticals under- or over-valued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Catalyst Pharmaceuticals shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48.4 million.

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM $133.5 million
Operating margin TTM 36.14%
Gross profit TTM $87.1 million
Return on assets TTM 15.15%
Return on equity TTM 23.42%
Profit margin 31.16%
Book value $1.93
Market capitalisation $676.5 million

TTM: trailing 12 months

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $3.27 up to $7.58. A popular way to gauge a stock's volatility is its "beta".

CPRX.US volatility(beta: 1.28)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.2772. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc.

Stocks similar to Catalyst Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site